

## PRESS RELEASE

### NOTICE PURSUANT TO ARTICLE 17 OF AIM ITALIA ISSUER REGULATION

Pisa, October 4<sup>th</sup>, 2018 – Pursuant to the Rules on Transparency and article 17 of AIM Italia Issuer Regulation, PharmaNutra S.p.A. (“**PharmaNutra**” or “**PHN**”) announces that, on October 4<sup>th</sup>, 2018, it received a notice from Azimut Libera Impresa SGR S.p.A., in the name and on behalf of the IPO CLUB fund, of the reduction, on September 27<sup>th</sup>, 2018, of the materiality threshold equal to 5% of share capital.

Specifically, the above shareholder stated that it held 326,068 ordinary shares, equal to 3.37% of PharmaNutra’s share capital, carrying voting rights, and that the decrease of its equity investment in PHN is the result of the block sale of a total of 170,000 PHN ordinary shares on September 27<sup>th</sup>, 2018. Furthermore, PharmaNutra notes that the above shareholder clarified that the transaction was performed to enable the entry of leading institutional investors, in order to diversify and further qualify PHN’s floating capital with other investors with a long-term investment horizon.

Based on the information received from shareholders and the information currently available to the company, the following shareholders hold more than 5% of PharmaNutra’s share capital with voting rights:

Direct shareholder	No. of shares	% of share capital with voting rights
Andrea Lacorte	2,972,500	30.70%
Roberto Lacorte	2,175,000	22.47%
Beda S.r.l. (*)	942,500	9.74%
Gianni Lazzarini	797,500	8.24%

Carlo Volpi is Beda S.r.l.’s sole quota-holder and director.

Pursuant to article 26 of AIM Italia Issuer Regulation, the names of PHN’s relevant shareholders are also available on the company’s website [www.pharmanutra.it](http://www.pharmanutra.it) / *Investors–relations* ([Share capital and shareholders](#)).

#### **PharmaNutra S.p.A.**

*Founded and headed by the Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra was established in 2003 to develop unique nutritional supplements and innovative nutritional devices, taking care of the entire production process, from the proprietary raw materials to the finished product. The effectiveness of its products has been demonstrated by numerous clinical studies, 79 of which published, with more than 5,000 patients treated. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 180 Medical Sales Representatives serving the medical profession, also devoted to exclusively marketing PharmaNutra products to pharmacies throughout Italy. Products are sold in over 70 countries abroad, through 35 partners selected from among the finest pharmaceutical companies. PharmaNutra leads in the production of iron-based nutritional supplements under the SiderAL® brand, boasting a number of important patents on Sucrosomial Technology®. Over the years, the Group has developed a precise strategy for the management and production of intellectual*

*property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence. <http://www.PharmaNutra.it>*

*For information:*

**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b

56122 Pisa

Tel. +39 050 7846500

Fax +39 050 7846524

[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

**Nomad & Specialist**

**CFO SIM S.p.A.**

Via dell'Annunciata 23/4

20121 Milan

Tel. +39 02 303431

[ecm@cfosim.com](mailto:ecm@cfosim.com)

**Press Office**

**Spriano Communication&Partners**

Tel. +39 02 83635708

Matteo Russo - Cristina Tronconi

Mob. +39 347 9834881 +39 346

0477901

[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)

[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)